We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > hypoparathyroidism

News List

Ascendis’ TransCon PTH shows promise in phase 2 hypoparathyroidism trial pharmaceutical-business-review
April 22, 2020
Ascendis Pharma said that its prodrug candidate TransCon PTH has met key objectives in the phase 2 PaTH Forward trial in adult subjects with hypoparathyroidism.
Shire granted EU conditional marketing authorisation for Natpar for the treatment of chronic hypopar cphi-online
April 27, 2017
Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism.
CHMP recommends EU Conditional Marketing Authorisation for Natpar for patients with chronic hypopara cphi-online
March 01, 2017
If approved, Natpar would be the first licensed recombinant parathyroid hormone in Europe for the management of chronic hypoparathyroidism, the only endocrine-deficiency disorder with no hormone treatment.